Ms. K. Priyatharcini
Post Graduate and Research Department of Biotechnolog | Assistant Professor
KP
Qualifications
- Ph.D. Cancer Immunology, SRM Institute of Science and Technology (2022–Present)
- M.Sc. Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research (2018–2020) – First Class with Distinction
- B.Sc. Microbiology, Madras Christian College (2015–2018) – First Class with Distinction
Work Experience
- Research Scholar, SRM Institute of Science and Technology, Chennai (01/2022–Present)
- Lab Trainee, Medall Diagnostics, Chennai (01/2020–12/2021)
Research Specialization
- Cancer Immunotherapy: Development, characterization, and therapeutic evaluation of anti-PD-L1 DNA aptamers for non-small cell lung cancer.
- Molecular Biology: Nucleic acids isolation (DNA & RNA), primer designing, conventional PCR, qRT-PCR data validation, agarose gel electrophoresis.
- Cell Culture & Cancer Biology: Mammalian cell culture, viability assays, dose optimization, apoptosis analysis, cell migration, invasion, and colony formation assays.
- Protein & Preclinical Evaluation: Western blotting, SDS-PAGE, ELISA, immunofluorescence, tumor xenograft models, and flow cytometry.
Areas of Expertise
01Ph.D.
02Degrees
01Researcher
06Publications
05Conferences
03Workshops
Awards & Recognition
🏆 Second Prize and Best Oral Presentation Award - 2nd International Conference on Genetics and Epigenetics of Cancer (ICGEC-2025)
🏆 Best Oral Presentation Award - Conference on Structural Biology and Drug Discovery (CSBDD 2024)
Academic Roles & Mentorship
- Assisted with laboratory instruction for undergraduate and postgraduate students
- Mentored student research activities and provided guidance in molecular biology and oncology
- Conducted preclinical research, cell culture maintenance, and protocol optimization
Identifiers
ORCID: 0000-0002-9273-1876
VIDWAN: N/A
Contact
Phone+91 73389 32200
LocationSembakkam, Chennai, Tamil Nadu
Research, Innovation & Output
Ph.D. Thesis: Aptamer-based cancer immunotherapy and immune checkpoint targeting: Development, characterization, and therapeutic evaluation of anti-PD-L1 DNA aptamers for non-small cell lung cancer through in silico, in vitro, and in vivo methods.
Publication (2025): Co-regulation of miRNA and lncRNA on immunosuppression gene: unveiling the regulatory networks in cancer. Nucleosides, Nucleotides & Nucleic Acids (Impact Factor: 1.2, Q3).
Publication (2025): Aptamers as therapeutic targets: prospects and progress in the treatment of cancers. Nucleosides, Nucleotides & Nucleic Acids (Impact Factor: 1.2, Q3).
Publication (2025): A novel anti-PD-L1 DNA aptamer, Apta35, enhances non-small cell lung cancer cell cytotoxicity and apoptosis through lung cancer-activated T lymphocytes. International Immunopharmacology (Impact Factor: 4.7, Q1).
Publication (2024): Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview. Medical Oncology (Impact Factor: 2.3, Q1).
Publication (2022): Long non-coding RNAs: An overview on miRNA sponging and its co-regulation in lung cancer. Molecular Biology Reports (Impact Factor: 2.8, Q2).
Publication (2022): Chitosan-tripolyphosphate nanoparticles encapsulated rutin targeting bacterial growth inhibition and its cytotoxicity on PANC-1 pancreatic adenocarcinoma cells. Journal of Applied Pharmaceutical Science (Impact Factor: 1.5, Q2).
Conference Presentations & Workshops
ICGEC-2025 (Mysuru): Oral Presentation - Therapeutic integration of an in-silico engineered anti-PD-L1 aptamer with targeted and immune activating therapies in NSCLC (Awarded 2nd Prize & Best Oral Presentation).
International Conference on Current Trends in Biotechnology (2024): Oral Presentation - Detection of cell cycle analysis of Apta35 PD-L1 aptamer in NCI-H460 cells.
CSBDD (2024): Oral Presentation - Development and validation of anti-PD-L1 aptamer in Non-Small Cell Lung Cancer in vitro (Best Oral Presentation Award).
International Conference on New Horizons Bioengineering (2024): Oral Presentation - Generation of the Anti-PD-L1 Aptamer to Enhance Apoptosis by Activated T-Cells Against Non-Small Cell Lung Cancer In Vitro.
CSBD (2023): Poster Presentation - Immune Checkpoint Inhibitors and Cancer Immunotherapy by Aptamers - An Overview.
BTDCTC-2019 (Loyola College): Poster Presentation - Association Between Advanced Glycated End (AGE) Products-Induced Diabetes and Colon Cancer.
Workshop (2025): Hands-on training program on advanced characterization techniques, Nanotechnology Research Centre (NRC), SRMIST.
Workshop (2022): Laboratory Animal Management and Handling, Centre for Animal Health Studies, TANUVAS.
Industrial Visit (2020): OFERR Nallayan Research Centre regarding Spirulina Cultivation.
Professional References
Dr. K.T. Ramya Devi: Assistant Professor, Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur | Email: ramyakanth3@gmail.com | Phone: +91 90250 06144